Avidity Biosciences, Inc. (RNA)
- Previous Close
26.26 - Open
27.11 - Bid 26.44 x 300
- Ask 28.02 x 100
- Day's Range
27.06 - 27.41 - 52 Week Range
21.51 - 56.00 - Volume
27,924 - Avg. Volume
1,526,095 - Market Cap (intraday)
3.261B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-2.89 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
66.69
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
www.aviditybiosciences.comRecent News: RNA
View More
Performance Overview: RNA
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNA
View MoreValuation Measures
Market Cap
3.16B
Enterprise Value
1.67B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
268.89
Price/Book (mrq)
2.22
Enterprise Value/Revenue
153.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.60%
Return on Equity (ttm)
-33.47%
Revenue (ttm)
10.9M
Net Income Avi to Common (ttm)
-322.3M
Diluted EPS (ttm)
-2.89
Balance Sheet and Cash Flow
Total Cash (mrq)
1.5B
Total Debt/Equity (mrq)
0.48%
Levered Free Cash Flow (ttm)
-197.47M